Weiss Ratings Reaffirms "Sell (D)" Rating for Maze Therapeutics (NASDAQ:MAZE)

Key Points

• Weiss Ratings has reaffirmed a "Sell (D)" rating for Maze Therapeutics (NASDAQ: MAZE) in a recent research note, reflecting ongoing concerns about the company's stock performance.
• Despite the "Sell" rating from Weiss, some analysts have upgraded their views, with JPMorgan raising its price objective from $27.00 to $37.00, and Guggenheim increasing their target from $19.00 to $34.00, both assigning "buy" ratings.
• Maze Therapeutics' stock has experienced significant fluctuations, with a 52-week low of $6.71 and a high of $29.66, and currently holds a consensus rating of "Buy" with an average price target of $33.83.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report)'s stock had its "sell (d)" rating restated by Weiss Ratings in a research note issued on Wednesday,Weiss Ratings reports.

Several other equities research analysts also recently commented on MAZE. JPMorgan Chase & Co. boosted their price objective on Maze Therapeutics from $27.00 to $37.00 and gave the company an "overweight" rating in a report on Monday, September 29th. Wall Street Zen upgraded Maze Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, August 16th. Guggenheim upped their price target on Maze Therapeutics from $19.00 to $34.00 and gave the stock a "buy" rating in a report on Monday, September 15th. BTIG Research upped their price target on Maze Therapeutics from $30.00 to $37.00 and gave the stock a "buy" rating in a report on Friday, September 12th. Finally, Wedbush started coverage on Maze Therapeutics in a report on Tuesday, July 8th. They set an "outperform" rating and a $17.00 price target for the company. Two equities research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average target price of $33.83.

Maze Therapeutics Stock Performance

NASDAQ MAZE opened at $28.59 on Wednesday. Maze Therapeutics has a 52 week low of $6.71 and a 52 week high of $29.66. The business has a 50 day moving average price of $18.71 and a 200-day moving average price of $13.99.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last released its quarterly earnings data on Tuesday, August 12th. The company reported ($0.77) EPS for the quarter, beating the consensus estimate of ($0.79) by $0.02.

Insider Activity at Maze Therapeutics

In other news, Director Richard H. Scheller sold 20,744 shares of Maze Therapeutics stock in a transaction on Monday, September 15th. The stock was sold at an average price of $22.37, for a total transaction of $464,043.28. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. New York State Common Retirement Fund purchased a new position in shares of Maze Therapeutics during the 1st quarter valued at $25,000. CWM LLC purchased a new position in shares of Maze Therapeutics during the 2nd quarter valued at $28,000. Corebridge Financial Inc. purchased a new stake in Maze Therapeutics during the 1st quarter worth about $48,000. Legal & General Group Plc lifted its holdings in Maze Therapeutics by 387.0% during the 2nd quarter. Legal & General Group Plc now owns 4,242 shares of the company's stock worth $52,000 after purchasing an additional 3,371 shares in the last quarter. Finally, Tower Research Capital LLC TRC lifted its holdings in Maze Therapeutics by 452.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,608 shares of the company's stock worth $57,000 after purchasing an additional 3,774 shares in the last quarter.

About Maze Therapeutics

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.